Benker G, Sandmann K, Tharandt L, Hackenberg K, Reinwein D
Horm Res. 1979;11(3):151-60. doi: 10.1159/000179050.
Sera of 7 patients with active acromegaly were fractionated by Sephadex G-100 chromatography and the effects of bromocriptine on the concentrations of total growth hormone (hGH) and its different molecular forms studied. Three immunoreactive peaks were observed, corresponding to molecular weights of about 20,000 ('little hGH'), 40,000 ('big hGH'), and more than 100,000 ('big big hGH') Following bromocriptine administration, there was significantly more reduction of 'little hGH' than of 'big big hGH'. Careful interpretation of these changes is required in view of the possible influences of sample storage and handling on hGH heterogeneity. We suggest that either bromocriptine acts differentially on the release of 'little' and 'big big hGH', or that these components differ in their metabolic half-life. However, even the suppression of 'little hGH' is insufficient to explain the clinical response of the disease to bromocriptine.
对7例活动期肢端肥大症患者的血清进行葡聚糖G - 100柱层析分离,并研究了溴隐亭对总生长激素(hGH)浓度及其不同分子形式的影响。观察到三个免疫反应峰,分别对应分子量约为20,000(“小分子hGH”)、40,000(“大分子hGH”)和超过100,000(“超大分子hGH”)的物质。给予溴隐亭后,“小分子hGH”的减少量明显多于“超大分子hGH”。鉴于样本储存和处理对hGH异质性可能产生的影响,需要对这些变化进行谨慎解读。我们认为,要么溴隐亭对“小分子”和“超大分子hGH”的释放作用不同,要么这些成分的代谢半衰期不同。然而,即使“小分子hGH”受到抑制,也不足以解释该疾病对溴隐亭的临床反应。